WILMINGTON,aaiPharma, which has been reorganizing and streamlining in the wake of financial troubles, has sold off the marketing rights of a drug.

aaiPharma announced Thursday morning it had sold US marketing rights for a kidney dialysis drug back to Sicor Pharmaceuticals.

Terms were not disclosed other than aaiPharma said it did receive “certain payments”.

“This transaction represents a small but important step in our initiative to rationalize and simplify our business,” said Ludo J. Reynders, aaiPharma’s CEO, in a statement.

aaiPharma: www.aaiPharma.com